2nd Department of Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Oncogene. 2010 May 27;29(21):3163-72. doi: 10.1038/onc.2010.80. Epub 2010 Mar 22.
Sporadic adrenocortical tumours are common, but their pathogenesis is poorly elucidated. In this study, we present a meta-analysis and review of gene expression microarray and comparative genome hybridization (CGH) studies performed to date on these tumours, including our own data. Data of whole genome microarray studies from altogether 164 tumours (97 benign, 67 malignant) and 18 normal tissues were reclassified and reanalysed. Significant gene sets and cytogenetic changes from publications without available genomic data were also examined including 269 benign, 215 malignant tumour and 30 normal tissues. In our experimental study, 11 tumour and four normal samples were analysed by parallel mRNA and CGH profiling. Data were examined by an integrative bioinformatics approach (GeneSpring, Gene Set Enrichment Analysis and Ingenuity Pathway Analysis softwares) searching for common gene expression changes and paralleling chromosome aberrations. Both meta-analysis of available mRNA and CGH profiling data and our experimental study revealed three major pathogenetic pathways: (1) cell cycle, (2) retinoic acid signalling (including lipopolysaccharide/Toll like receptor 4 pathway), (3) complement system and antigen presentation. These pathways include novel, previously undescribed pathomechanisms of adrenocortical tumours, and associated gene products may serve as diagnostic markers of malignancy and therapeutic targets.
散发性肾上腺皮质肿瘤很常见,但它们的发病机制尚未阐明。在本研究中,我们对迄今为止针对这些肿瘤进行的基因表达微阵列和比较基因组杂交 (CGH) 研究进行了荟萃分析和综述,包括我们自己的数据。重新分类和重新分析了来自总共 164 个肿瘤(97 个良性,67 个恶性)和 18 个正常组织的全基因组微阵列研究数据,以及来自没有可用基因组数据的出版物的显著基因集和细胞遗传学变化,包括 269 个良性、215 个恶性肿瘤和 30 个正常组织。在我们的实验研究中,通过平行的 mRNA 和 CGH 分析对 11 个肿瘤和 4 个正常样本进行了分析。通过综合生物信息学方法(GeneSpring、基因集富集分析和Ingenuity Pathway Analysis 软件)检查了数据,以寻找常见的基因表达变化并与染色体畸变平行。对现有 mRNA 和 CGH 分析数据的荟萃分析和我们的实验研究都揭示了三个主要的发病途径:(1)细胞周期,(2)视黄酸信号(包括脂多糖/Toll 样受体 4 途径),(3)补体系统和抗原呈递。这些途径包括肾上腺皮质肿瘤的新的、以前未描述的病理机制,并且相关的基因产物可以作为恶性肿瘤的诊断标志物和治疗靶点。